Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1388-1396

  Sculier, J P ^a   Paesmans, M ^a   Thiriaux, J ^a   Lecomte, J ^a   Bureau, G ^a   Giner, V ^a   Efremidis, A ^a   Lafitte, J J ^a   Berchier, M C ^a   Alexopoulos, C G ^a   Zacharias, C ^a   Mommen, P ^a   Ninane, V ^a   Klastersky, J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 7144251165     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1388     Document Type: Article

References (30)

1. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
2. Grilli R, Andrew D, Oxman AD, et al: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough ? J Clin Oncol 11:1866-1872, 1993
3. Marino P, Pampallona S, Preatoni A, et al: Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 106:861-865, 1994
4. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
5. Donnadieu N, Paesmans M, Sculier JP: Chimiothérapie des cancers bronchiques non à petites cellules. Méta-analyse de la littérature en fonction de l'extension de la maladie. Rev Mal Resp 8:197-204, 1991
6. Gralla RJ, Casper ES, Kelsen DP, et al: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95:414-420, 1981
7. Klastersky J, Sculier JP, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 4:1780-1786, 1986
8. Shinkai T, Saijo N, Eguchi K, et al: Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: A randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res (Gann) 77:182-189, 1986
9. Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
10. Sculier JP, Klastersky J, Giner V, et al: Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 12:353-359, 1994
11. Klastersky J, Sculier JP, Bureau G, et al: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087-1092, 1989
12. Crino L, Tonato M, Darwish S, et al: A randomized trial of three cisplatin-containing regimens in advanced non-small cell lung cancer (NSCLC): A study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 26:52-56, 1990
13. Kawahara M, Furuse K, Kodama N, et al: A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68:714-719, 1991
14. Machin D, Campbell MJ: Statistical Tables for the Design of Clinical Trials. Oxford, United Kingdom, Blackwell Scientific, 1987
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc J 53:457-481, 1958
16. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized trials requiring prolonged observation of each patient II. Analysis and examples. Br J Cancer 35:1-39, 1977
17. Cox DR, Oakes D: Analysis of Survival Data. London, United Kingdom, Chapman & Hall, 1984
18. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989
19. Sculier JP, Paesmans M, Bureau G, et al: Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: A phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 11:1858-1865, 1993
20. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
21. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
22. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995
23. Paccagnella A, Favaretto A, Brandes A, et al: Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma: A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 65:2631-2634, 1990
24. Kosmidis P, Mylonakis N, Skarlos DV, et al: A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small cell lung cancer. Ann Oncol 5:159-162, 1994
25. Erkisi M, Doran F, Burgut R, et al: A randomized trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer. Lung Cancer 12:237-246, 1995
26. Klastersky J, Sculier JP, Lacroix H, et al: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562, 1990
27. Klastersky J, Sculier JP, Ries F, et al: A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracil: A regimen associated with major toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 11:373-384, 1994
28. Quezado ZMN, Wilson WH, Cunnion RE, et al: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31-36, 1993
29. Borges M, Sculier JP, Paesmans M: Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. Lung Cancer 16:21-33, 1996
30. Paesmans M, Sculier JP, Libert P, et al: Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 13:1221-1230, 1995